Seres Therapeutics Inc to Post FY2022 Earnings of ($0.30) Per Share, Oppenheimer Forecasts (MCRB)
Seres Therapeutics Inc (NASDAQ:MCRB) – Research analysts at Oppenheimer issued their FY2022 EPS estimates for shares of Seres Therapeutics in a research note issued to investors on Thursday. Oppenheimer analyst M. Breidenbach anticipates that the biotechnology company will post earnings per share of ($0.30) for the year. Oppenheimer has a “Outperform” rating and a $19.00 price objective on the stock.
Several other analysts have also recently commented on the company. Zacks Investment Research cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. ValuEngine cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 21st. Citigroup assumed coverage on Seres Therapeutics in a research report on Thursday, October 12th. They issued a “positive” rating and a $19.00 target price for the company. Cowen reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Monday, October 2nd. Finally, Seaport Global Securities reaffirmed a “buy” rating and issued a $20.00 target price on shares of Seres Therapeutics in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. Seres Therapeutics has a consensus rating of “Buy” and a consensus price target of $18.00.
Seres Therapeutics (NASDAQ MCRB) traded down $0.37 on Monday, hitting $10.24. The stock had a trading volume of 127,735 shares, compared to its average volume of 189,600. The company has a market cap of $430.02, a price-to-earnings ratio of -4.83 and a beta of 0.22. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics has a 1-year low of $8.85 and a 1-year high of $17.42.
Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.22. The business had revenue of $23.00 million during the quarter, compared to analyst estimates of $17.29 million. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. The company’s revenue was up 76.9% compared to the same quarter last year. During the same period last year, the company posted ($0.46) EPS.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Voya Investment Management LLC acquired a new stake in Seres Therapeutics during the second quarter valued at $114,000. Cubist Systematic Strategies LLC acquired a new stake in Seres Therapeutics during the third quarter valued at $170,000. Aperio Group LLC acquired a new stake in Seres Therapeutics during the third quarter valued at $191,000. Ironwood Investment Management LLC acquired a new stake in Seres Therapeutics during the third quarter valued at $221,000. Finally, Advisor Group Inc. boosted its position in Seres Therapeutics by 100.7% during the second quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 7,050 shares during the last quarter. 75.94% of the stock is owned by hedge funds and other institutional investors.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.